E
EpicentRx Inc
A clinical-stage immuno-oncology company
About EpicentRx Inc
EpicentRx is a biotechnology company focused on developing innovative immunotherapies and oncolytic viruses to treat various types of cancer. The company operates in the biopharmaceutical market, primarily serving patients with small cell lung cancer and other tumor types. EpicentRx's core product, RRx-001, is a next-generation small molecule immunotherapeutic currently in Phase 3 clinical trials. The company also pioneers the development of oncolytic viruses tailored to individual patients' tumors, aiming to enhance both innate and adaptive immunity with minimal toxicity. EpicentRx generates revenue through licensing agreements, such as its partnership with SciClone Pharmaceuticals for the Greater China market, and through the development and commercialization of its proprietary therapies. The business model is centered around research and development, clinical trials, and strategic partnerships to bring their innovative treatments to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- San Diego, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 41.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Nov 2022 | $0 | — | FightMND | ↗ |
| GRANT✓Other financing | Jul 2022 | $500K | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
Growth signals
Latest recorded traffic for EpicentRx Inc is 2.8K monthly website visits, down 22.2% over the last three months. EpicentRx Inc's team declined 15.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Michael J. Fox Foundation for Parkinson's Research
FightMND
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EpicentRx Inc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EpicentRx Inc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.